Akolkar DB, et al. - Researchers assessed treatment response in a basket of 18 individuals with different advanced refractory solid organ malignancies, who received personalized treatments on the basis of Encyclopedic Tumor Analysis (ETA) investigations in order to check whether administration of Androgen Receptor (AR) antagonists indicated by ETA in synergistic combination with cytotoxic, targeted or other endocrine agents could afford clinical advantage for refractory cancers. Nine individuals exhibited Partial Response (PR) along with an Objective Response Rate (ORR) of 50%. Five individuals revealed stable disease for ≥ 3 months, whereas four exhibited disease progression. In two individuals disease progressed at ~60 days and in the remaining two, progression was observed at > 120 days. Treatments were well endured with no critical adverse events. In conclusion, androgen addicted, refractory solid organ tumors reacted to combinations of cytotoxic, targeted and endocrine agents along with AR antagonists supervised by ETA.